Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy
- PMID: 1877457
- DOI: 10.1016/0002-8703(91)90527-o
Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy
Abstract
Myocardial high-energy phosphate metabolism in patients with dilated cardiomyopathy (DCM) of ischemic or idiopathic etiology was assessed at rest by one-dimensional phase-encoded 31P-nuclear magnetic resonance (NMR) spectroscopy studies performed in conjunction with 1H imaging in 20 patients with DCM and in 12 normal volunteers. The measured values of anterior myocardial phosphocreatine/beta-adenosine triphosphate (PCr/beta-ATP), corrected for partial saturation and contamination of the spectra by blood metabolites, averaged 1.80 +/- 0.06 (mean +/- SE) in normal volunteers and 1.46 +/- 0.07 in the patients overall, a highly significant (p less than 0.001) decrease. In patients with DCM accompanied by coronary artery disease (n = 9), the PCr/beta-ATP ratio averaged 1.53 +/- 0.07, while in those with DCM alone it was 1.41 +/- 0.12 (n = 11), a value that was not significantly different. There was no significant correlation (r = 0.34) between myocardial PCr/ATP ratio and left ventricular ejection fraction in patients. These studies demonstrate that myocardial PCr/ATP ratios are reduced at rest in human ischemic and idiopathic dilated cardiomyopathy.
Similar articles
-
Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy.J Am Coll Cardiol. 2002 Oct 2;40(7):1267-74. doi: 10.1016/s0735-1097(02)02160-5. J Am Coll Cardiol. 2002. PMID: 12383574
-
Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.Circulation. 1997 Oct 7;96(7):2190-6. doi: 10.1161/01.cir.96.7.2190. Circulation. 1997. PMID: 9337189
-
31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.Circulation. 1992 Dec;86(6):1810-8. doi: 10.1161/01.cir.86.6.1810. Circulation. 1992. PMID: 1451253
-
MR spectroscopy of the heart.Radiol Med. 2006 Dec;111(8):1025-34. doi: 10.1007/s11547-006-0102-8. Epub 2006 Dec 20. Radiol Med. 2006. PMID: 17171530 Review. English, Italian.
-
Cardiac magnetic resonance spectroscopy: potential clinical applications.Herz. 2000 Jun;25(4):452-60. doi: 10.1007/s000590050037. Herz. 2000. PMID: 10948781 Review.
Cited by
-
Low Tissue Creatine: A Therapeutic Target in Clinical Nutrition.Nutrients. 2022 Mar 15;14(6):1230. doi: 10.3390/nu14061230. Nutrients. 2022. PMID: 35334887 Free PMC article. Review.
-
Dilated Cardiomyopathy: Phosphorus 31 MR Spectroscopy at 7 T.Radiology. 2016 Nov;281(2):409-417. doi: 10.1148/radiol.2016152629. Epub 2016 Jun 20. Radiology. 2016. PMID: 27326664 Free PMC article.
-
Phenotyping heart failure by cardiac magnetic resonance imaging of cardiac macro- and microscopic structure: state of the art review.Eur Heart J Cardiovasc Imaging. 2023 Sep 26;24(10):1302-1317. doi: 10.1093/ehjci/jead124. Eur Heart J Cardiovasc Imaging. 2023. PMID: 37267310 Free PMC article. Review.
-
Cardiac 31P MR spectroscopy: development of the past five decades and future vision-will it be of diagnostic use in clinics?Heart Fail Rev. 2023 Mar;28(2):485-532. doi: 10.1007/s10741-022-10287-x. Epub 2022 Nov 24. Heart Fail Rev. 2023. PMID: 36427161 Review.
-
ATP flux through creatine kinase in the normal, stressed, and failing human heart.Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):808-13. doi: 10.1073/pnas.0408962102. Epub 2005 Jan 12. Proc Natl Acad Sci U S A. 2005. PMID: 15647364 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
